紫杉醇脂质体与白蛋白结合型紫杉醇治疗复发性卵巢癌近期疗效与安全性评价

Evaluation of the Efficacy and Safety of Abraxane and Paclitaxel Liposome in the Treatment of Recurrent Ovarian Cancer

目的:观察紫杉醇脂质体与白蛋白结合型紫杉醇治疗复发性卵巢癌的近期疗效,评价其安全性。方法:复发性卵巢癌患者60例,随机分为观察组和对照组(各30例)。观察组予以紫杉醇脂质体联合奈达铂治疗,对照组采用白蛋白结合型紫杉醇联合奈达铂方案,比较两组治疗总有效率及其毒副作用。结果:观察组治疗总有效率(90.00%)高于对照组(66.67%),毒副作用发生率(10.00%)低于对照组(36.67%),差异具有统计学意义(P<0.05)。结论:紫杉醇脂质体联合奈达铂治疗复发性卵巢癌安全、有效。

Objective： To evaluate the efficacy and safety of paclitaxel liposome and Abraxane in treat- ment of recurrent ovarian cancer. Methods. 60 cases of recurrent ovarian cancer treated were selected, who were randomly divided into 2 groups with 30 cases in each group. The observation group were treated with paclitaxel liposome combined with Nedaplatin, the control group were treated with Abraxane combined with Nedaplatin. Total effective rate and side effects of the two groups were compared. Results： The total effective rate of the observation group （90.00%）was higher than that of the control group（66.76%）. After treatment, the adverse effect of the observation group（10.00 %） was lower than that in the control group（36.67 %）（P〈 0.05）. Conclusion： Paclitaxel liposome combined nedapiatin is safe and effective for treating recurrent ovarian cancer.